Response Genetics, Inc. is engaged in the research and development of clinical diagnostic tests for cancer. The company is headquartered in Los Angeles, California and currently employs 96 full-time employees. The company went IPO on 2007-06-05. The firm is engaged in the research, development, marketing and sale of pharmacogenomic tests for use in the treatment of cancer. To generate pharmacogenomic information from patient specimens for these tests, the Company uses its own methods for the extraction and analysis of nucleic acids and accessing the genetic information available from each patient sample. The firm's platforms include analysis of single biomarkers using the polymerase chain reaction method, as well as gene interrogation using microarray methods and fluorescence in situ hybridization (FISH) from paraffin or frozen tissue specimens. The firm is engaged in selling ResponseDX diagnostic testing products. The firm provides pharmacogenomic clinical trial testing services to pharmaceutical companies in the United States, Asia and Europe.
Follow-Up Questions
What is Response Genetics Inc (RGDXQ)'s P/E Ratio?
The P/E ratio of Response Genetics Inc is 0
Who is the CEO of Response Genetics Inc?
Mr. Thomas Bologna is the Chairman of the Board of Response Genetics Inc, joining the firm since 2011.
What is the price performance of RGDXQ stock?
The current price of RGDXQ is $0, it has decreased 0% in the last trading day.
What are the primary business themes or industries for Response Genetics Inc?
Response Genetics Inc belongs to Life Sciences Tools & Services industry and the sector is Health Care
